MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.130
-0.060
-1.88%
Closed 16:00 02/21 EST
OPEN
3.134
PREV CLOSE
3.190
HIGH
3.140
LOW
3.065
VOLUME
11.62K
TURNOVER
--
52 WEEK HIGH
4.360
52 WEEK LOW
2.000
MARKET CAP
32.55M
P/E (TTM)
-1.7768
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLBS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLBS stock price target is 10.50 with a high estimate of 18.50 and a low estimate of 6.00.

EPS

CLBS News

More
  • Caladrius Biosciences (CLBS) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 02/11 17:14
  • Caladrius Biosciences to Participate at Upcoming February Conferences
  • GlobeNewswire · 02/03 13:30
  • The Market Timing Secrets No One Talks About - January 27, 2020
  • Zacks · 01/27 14:17
  • Does Caladrius Biosciences, Inc. (NASDAQ:CLBS) Have A Particularly Volatile Share Price?
  • Simply Wall St. · 01/21 12:35

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About CLBS

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
More

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.